Charles Hoeffer portrait
Associate Professor
Institute for Behavioral Genetics • Integrative Physiology

Institute for Behavioral Genetics
University of Colorado Boulder
447 UCB
Boulder, CO 80309-0447

Research Interests:

Understanding the cellular and molecular basis for neurological disorder and neurodegenerative disease.

Active Grants:

  • NIA R01 AG064465-01 (MPI: Hoeffer, Link, Opp) 7/1/2019-6/30/2024. Sleep Disruption and Alzheimer's Disease Pathology. Role: PI
  • NIA R01 AG064465-01 SUPPLEMENT2 (MPI: Hoeffer, Link, Opp) 8/1/2022-7/31/2024. Sleep Disruption and Alzheimer's Disease Pathology/ Links between AD, DS and sleep disruption. Role: PI
  • AB Nexus Grant (MPI: Huntsman, Hoeffer) Period 12/1/2021-11/30/2022 Understanding AKT1 function regulating interneuronal activity involved in E/I balance. Role: PI
  • NIDA R21/R33 DA055781-A1 (Hoeffer, Ehringer, Stitzel) 9/15/2022-9/14/2027. Role of glial expression in nicotine behaviors for genes identified through human GWAS Role: PI
  • NIA RF1AG064465-S2 (Hoeffer, Opp, Link) 04/01/2022-3/31/2023 Sleep Disruption in Down Syndrome-related Alzheimer’s Disease. Role: PI
  • Lab Venture Challenge (LVC), Venture Partners at CU Boulder and the Colorado Office of Economic Development and International Trade (OEDIT) Advanced Industries Program, (MPI Hoeffer, Parker, Van Alstyne) 3/1/2024-2/28/2026. New treatment for dementia with peptide therapeutics targeting tau aggregation. Role: PI
  • NI23013. AFAR (Evans) 01/01/2024-12/31/2026 ,Gene-gene interaction associations with frailty to identify core genes of aging and their biological context. Role: Co-Investigator
  • NIH R01 AG083268 (Hoeffer) 9/1/2023-8/31/2028. Sleep abnormalities in Down Syndrome-related Alzheimer's disease. Role: PI
  • NIH R01 NS131660 (Whiteley) 4/1/2023-3/31/2027. Investigation of UBQLN2-dependent changes to neuronal health and function in ALS-FTD. Role: Co-Investigator

Additional Resources:

Current CV

Dr. Hoeffer speaks on Molecular Signaling and Neurological Disorders: